Optimization of evening insulin dose in patients using the short-acting insulin analog lispro

What Was Tested

Researchers studied Insulin Lispro and NPH Insulin (isophane) in this randomized controlled trial publication.

Who Took Part

The study group was 13 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The three regimens were tested in random order.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Insulin Lispro study: the patients and staff both knew the treatment.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include 3-Hydroxybutyric Acid, Blood Glucose, Circadian Rhythm, Diabetes Mellitus, Type 1, Hydroxybutyrates, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro and NPH Insulin (isophane) in 13 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page and the NPH Insulin (isophane) compound page, all human trials.